IS THERE A PLACE FOR ANTI-NUCLEOSOME ANTIBODY ASSESSMENT IN SCLERODERMA?

Introduction. The hallmarks of systemic sclerosis (SSc) include microangiopathy, autonomic dysfunction, as well as immune disturbance and the widespread fibrosis of the skin and visceral organs. While the significance of SSc-specific autoantibodies such as anti-centromere and anti-topoisomerase I has long been demonstrated, the clinical relevance of non-specific autoantibodies remains a matter of debate. Our primary objective was to assess the relationships between non-SSc-specific antibody titers and the clinical characteristics of scleroderma patients. Secondary objectives included a comparison between SSc, SLE and healthy controls (HC) with respect to autoantibody values, as well as the analysis of the immune disturbance in elderly individuals in the 3 groups. Material and method. We conducted a cross-sectional study in which we recruited 67 adult patients with SSc, 67 age and gender-matched individuals with SLE and healthy controls (HC). Biological samples (venous blood) were collected in order to determine the levels of anti-SSA/Ro, anti-SSB/La, anti-U1RNP and anti-nucleosome antibodies (ELISA). We recorded the presence of digital ulcers (DUs), ILD (thoracic X-rays), and PAH (Doppler echocardiography) in the scleroderma cohort. Results. The frequency of anti-nucleosome antibody positivity in the scleroderma group exceeded our expectations, resembling that of lupus patients. Moreover, our findings indicate an association between serum anti-nucleosome antibody titers and SSc-related cardiopulmonary involvement. Anti-U1RNP antibodies were linked to PAH. We did not identify a notable relationship between the 4 autoantibodies studied and DUs. However, the latter were significantly more frequent in male patients. Although elderly individuals with scleroderma did not demonstrate a significantly decreased autoantibody production, lupus patients over 60 years of age exhibited a decline in anti-nucleosome antibody titers. Discussions. Earlier research reported an association between anti-nucleosome and anti-U1RNP antibodies with SSc-related cardiopulmonary impairment. Moreover, male gender is currently regarded as an important risk factor for the development of scleroderma DUs. Conclusions. Recent research provides new insights on the pathogenic processes of autoimmune rheumatic diseases, in an attempt to identify potential risk factors for organ involvement. Our study confirms the link between anti-nucleosome antibodies and cardiopulmonary involvement in the SSc population. Moreover, the impact of immunosenescence on the dynamics of autoantibody production in connective tissue diseases remains in need of further investigation

A Scoping Review of the Relationship between Intermittent Fasting and the Human Gut Microbiota: Current Knowledge and Future Directions

Intermittent fasting (IF) has been promoted as an alternative to dietary caloric restriction for the treatment of obesity. IF restricts the amount of food consumed and improves the metabolic balance by synchronizing it with the circadian rhythm. Dietary changes have a rapid effect on the gut microbiota, modulating the interaction between meal timing and host circadian rhythms. Our paper aims to review the relationships between IF and human gut microbiota. In this study, the primary area of focus was the effect of IF on the diversity and composition of gut microbiota and its relationship with weight loss and metabolomic alterations, which are particularly significant for metabolic syndrome characteristics. We discussed each of these findings according to the type of IF involved, i.e., time-restricted feeding, Ramadan fasting, alternate-day fasting, and the 5:2 diet. Favorable metabolic effects regarding the reciprocity between IF and gut microbiota changes have also been highlighted. In conclusion, IF may enhance metabolic health by modifying the gut microbiota. However additional research is required to draw definitive conclusions about this outcome because of the limited number and diverse designs of existing studies

Assessment of preoperative and postoperative prealbumin in thoracic surgery – a two months experience in a Romanian university hospital / Evaluarea preoperatorie şi postoperatorie a prealbuminei în chirurgia toracică - experiența de 2 luni a unui spital universitar din România

Malnutriția este o constatare frecventă și importantă în secțiile chirurgicale. Deşi consecințele sale includ complicații postoperatorii și costuri mai mari, evaluarea nutrițională nu face parte din protocoalele preoperatorii de rutină. Evaluarea nutriţională include parametri clinici și biologici și este vitală pentru a începe tratamentul și a îmbunătăți rezultatele. Prealbumina este în prezent recunoscută ca un marker fidel al malnutriției şi este inclusă în ghidurile de practică. Unul dintre cele mai importante aspecte legate de prealbumină este faptul că variațiile sale în timp sunt mai valoroase decât valorile absolute. Scopul acestui studiu a fost de a evalua și compara evoluția nutrițională perioperatorie a pacienţilor care necesită intervenţii de chirurgie toracică, cu şi fără cancer, folosind prealbumina - preoperator și postoperator - ca marker principal. Treizeci şi şase de pacienţi de la Clinica de Chirurgie Toracică au fost evaluaţi înainte de intervenţia chirurgicală, prin indicele de masă corporală, scorul de risc nutriţional Subjective Global Assessment (SGA) și parametri biochimici de rutină. Prealbumina a fost evaluată înainte de intervenţia chirurgicală şi la 3 zile după operaţie.Vârstă, durata spitalizării postoperatorii și prezența complicaţiilor au fost notate. Pacienții cu cancer (n = 19) au fost semnificativ mai în vârstă decât pacienții fără cancer (p = 0,007) și au fost mai frecvent, dar nu în mod semnificativ, evaluaţi prin SGA ca fiind malnutriţi (42,1% față de 11,6%). Prealbumina preoperator și alți parametri nu diferă semnificativ între grupuri. Cu toate acestea, a existat o scădere semnificativă a prealbuminei postoperator doar la pacienții cu cancer. Prin urmare, prealbumina s-a dovedit a fi valoroasă în evaluarea malnutriţiei acute la pacienţii cu cancer, în special prin monitorizarea variaţiilor în timp, ceea ce ar putea fi util în planificarea tratamentului nutriţional

Validation of the Dutch Eating Behavior Questionnaire in a Romanian Adult Population

(1) Background: Obesity, part of the triple global burden of disease, is increasingly attracting research on its preventive and curative management. Knowledge of eating behavior can be useful both at the individual level (to individualize treatment for obesity) and the population level (to implement more suitable food policies). The Dutch Eating Behavior Questionnaire (DEBQ) is a widely used international tool to assess eating behavior, i.e., emotional, external and restricted eating styles. The aim of this study was to validate the Romanian version of DEBQ, as obesity is a major concern in Romania. (2) Methods: Our study tested the psychometric properties of the Romanian version of DEBQ on an adult population and explored the associations of eating behavior with weight status (3) Results: The study showed a factor load similar to the original version of the questionnaire and a very good internal validity (Cronbach’s alpha fidelity coefficient greater than 0.8 for all scales of the questionnaire) for the Romanian version of DEBQ and showed that all of the scales positively correlated with body mass index in both men and women. (4) Conclusions: This study will enable the use of the DEBQ Romanian version on the adult population of Romania where the findings could be incorporated into developing better strategies to reduce the burden of nutrition-related diseases

Survival Prediction in Diabetic Foot Ulcers: A Machine Learning Approach

Our paper proposes the first machine learning model to predict long-term mortality in patients with diabetic foot ulcers (DFUs). The study includes 635 patients with DFUs admitted from January 2007 to December 2017, with a follow-up period extending until December 2020. Two multilayer perceptron (MLP) classifiers were developed. The first MLP model was developed to predict whether the patient will die in the next 5 years after the current hospitalization. The second MLP classifier was built to estimate whether the patient will die in the following 10 years. The 5-year and 10-year mortality models were based on the following predictors: age; the University of Texas Staging System for Diabetic Foot Ulcers score; the Wagner–Meggitt classification; the Saint Elian Wound Score System; glomerular filtration rate; topographic aspects and the depth of the lesion; and the presence of foot ischemia, cardiovascular disease, diabetic nephropathy, and hypertension. The accuracy for the 5-year and 10-year models was 0.7717 and 0.7598, respectively (for the training set) and 0.7244 and 0.7087, respectively (for the test set). Our findings indicate that it is possible to predict with good accuracy the risk of death in patients with DFUs using non-invasive and low-cost predictors

Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response

Background and Objectives: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in assessing evolution, prognosis and monitoring of hepatic disease, especially after treatment with direct-acting antivirals (DAAs). The aim of this study was to assess the link between patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism and the degree of hepatic steatosis and fibrosis in patients with chronic HCV infection, as well as changes in steatosis and fibrosis three monthsafter obtaining a sustained viral response (SVR). Materials and Methods:Ourstudy included 100 patients with chronic hepatitis C (CHC) infection and compensated cirrhosis who received DAA treatment and who were evaluated using Fibromax prior to and 3 months after SVR. The influence of PNPLA3 (CC, CG, GG) genotype among these patients on the degree of post-treatment regression of steatosis and fibrosis was assessed. Results: Regression was noticed in the degree of both hepatic steatosis and hepatic fibrosis post-DAA treatment (three months after SVR). Analysis of the correlation between PNPLA3 genotype and fibrosis indicated that the average level of fibrosis (F) before DAA treatment was higher in patients with the GG genotype than in patients with the CC or CG genotype. Three months after SVR, the average level of fibrosis decreased; however, it remained significantly increased in GG subjects compared to that in CC or CG patients. The degree of hepatic steatosis before treatment was not significantly different among patients with different PNPLA3 genotypes, and no significant correlations were observed three months after SVR. Conclusions: The genetic variants of PNPLA3 influence the evolution of hepatic fibrosis. The GG subtype plays an important role in the degree of hepatic fibrosis both before and after treatment (three months after SVR)and could be a prognostic marker for assessment of post-SVR evolution

Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response

Background and Objectives: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in assessing evolution, prognosis and monitoring of hepatic disease, especially after treatment with direct-acting antivirals (DAAs). The aim of this study was to assess the link between patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism and the degree of hepatic steatosis and fibrosis in patients with chronic HCV infection, as well as changes in steatosis and fibrosis three monthsafter obtaining a sustained viral response (SVR). Materials and Methods:Ourstudy included 100 patients with chronic hepatitis C (CHC) infection and compensated cirrhosis who received DAA treatment and who were evaluated using Fibromax prior to and 3 months after SVR. The influence of PNPLA3 (CC, CG, GG) genotype among these patients on the degree of post-treatment regression of steatosis and fibrosis was assessed. Results: Regression was noticed in the degree of both hepatic steatosis and hepatic fibrosis post-DAA treatment (three months after SVR). Analysis of the correlation between PNPLA3 genotype and fibrosis indicated that the average level of fibrosis (F) before DAA treatment was higher in patients with the GG genotype than in patients with the CC or CG genotype. Three months after SVR, the average level of fibrosis decreased; however, it remained significantly increased in GG subjects compared to that in CC or CG patients. The degree of hepatic steatosis before treatment was not significantly different among patients with different PNPLA3 genotypes, and no significant correlations were observed three months after SVR. Conclusions: The genetic variants of PNPLA3 influence the evolution of hepatic fibrosis. The GG subtype plays an important role in the degree of hepatic fibrosis both before and after treatment (three months after SVR)and could be a prognostic marker for assessment of post-SVR evolution